Riskpilot← Back to searchSign inGet full accessMEDNORDIX AS
ASActiveOrg 983924646Rolfsbuktveien 2, 1364 FornebuWholesale of pharmaceutical and medical goods · NACE 4646Est. 20010 employees
Revenue 2024
NOK 1,8M
+6% vs 2023
EBITDA margin
-1.9%
-171% vs 2023
Equity ratio
41.3%
Financial strength
Net profit 2024
NOK -46K
-288% vs 2023
| Revenue | NOK 1,8M | +6% |
| EBITDA | NOK -35K | -171% |
| Net profit | NOK -46K | -288% |
| Total assets | NOK 424K | -44% |
| Equity | NOK 175K | -21% |
| Employees | 0 | — |
Legal name
MEDNORDIX AS
Org number
983924646
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. desember 2001
Share capital
NOK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Salg av produkter innen sykepleie, drive konsulentvirksomhet innen området sykepleie samt å eie og forvalte så vel løsøre som fast eiendom og å utføre annen virksomhet som har naturlig sammenheng med dette.
Address
Rolfsbuktveien 2, 1364 Fornebu
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 302 | 2 147 | 0 | 1 708 | 1 815 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 109 | 79 | 0 | 49 | −35 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 109 | 79 | 0 | 49 | −35 |
| Net financials | −34 | 1 | 0 | −17 | −12 |
| Profit before tax | 75 | 79 | 0 | 32 | −46 |
| Tax | 16 | 17 | −0 | 7 | −0 |
| Net profit | 58 | 62 | 0 | 25 | −46 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 506 | 974 | — | 758 | 424 |
| Equity | 349 | 411 | — | 221 | 175 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 157 | 564 | 0 | 537 | 249 |
| Total debt | 157 | 564 | 0 | 537 | 249 |
EBITDA margin
-1.9%
This company
15.8%
Market median
-112% vs market
20202024
Equity ratio
41.3%
This company
38.2%
Market median
+8% vs market
20202024
Return on equity
-26.4%
This company
18.4%
Market median
-243% vs market
20202024
Net profit margin
-2.5%
This company
8.1%
Market median
-131% vs market
20202024
Asset turnover
4.28×
This company
1.12×
Market median
+282% vs market
20202024
Debt / equity
1.42×
This company
0.62×
Market median
-129% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-07-01 – 2022-06-30
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2019-07-01 – 2020-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
UG Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (1) | ||
LM Deputy Member | Deputy Member | 2001 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nordic Adcare Group Ab | Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MEDNORDIX AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulf Gunnar Gunnarsson Järnberg | Chief Executive Officer | 0 companies |
| Lena Margaretha Rönnqvist | Deputy Member | 0 companies |
| Per Magnus Eriksson | Chairman | 0 companies |
| José Carlos Lorente Zarebski | Board of Directors | 0 companies |
| Lars Anders Rønnqvist | Board of Directors | 0 companies |